Brokerages expect Neos Therapeutics, Inc. (NASDAQ:NEOS) to report earnings per share (EPS) of ($0.70) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Neos Therapeutics’ earnings. Neos Therapeutics reported earnings of ($1.61) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 56.5%. The firm is expected to announce its next earnings results on Thursday, November 9th.

On average, analysts expect that Neos Therapeutics will report full year earnings of ($3.06) per share for the current financial year, with EPS estimates ranging from ($3.30) to ($2.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.95) to ($0.51). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Neos Therapeutics.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. The business had revenue of $4.91 million during the quarter.

NEOS has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Cantor Fitzgerald initiated coverage on shares of Neos Therapeutics in a research report on Monday, July 31st. They issued an “overweight” rating and a $20.00 price target for the company. Wells Fargo & Company set a $14.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research report on Wednesday. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. Finally, Royal Bank Of Canada set a $12.00 price objective on shares of Neos Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Neos Therapeutics currently has an average rating of “Hold” and a consensus target price of $14.00.

Shares of Neos Therapeutics (NASDAQ NEOS) traded up 2.67% during trading on Friday, hitting $7.70. The stock had a trading volume of 358,140 shares. Neos Therapeutics has a 12-month low of $4.85 and a 12-month high of $9.60. The stock’s 50-day moving average is $8.70 and its 200-day moving average is $8.70. The stock’s market capitalization is $216.22 million.

WARNING: “Brokerages Anticipate Neos Therapeutics, Inc. (NEOS) Will Announce Earnings of -$0.70 Per Share” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/22/brokerages-anticipate-neos-therapeutics-inc-neos-will-announce-earnings-of-0-70-per-share.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board acquired a new position in Neos Therapeutics during the second quarter valued at approximately $102,000. OMERS ADMINISTRATION Corp acquired a new position in Neos Therapeutics during the second quarter valued at approximately $110,000. Dynamic Technology Lab Private Ltd acquired a new position in Neos Therapeutics during the second quarter valued at approximately $118,000. Tudor Investment Corp ET AL acquired a new position in Neos Therapeutics during the second quarter valued at approximately $146,000. Finally, Rhumbline Advisers raised its position in Neos Therapeutics by 13.6% during the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after purchasing an additional 2,441 shares in the last quarter. Institutional investors and hedge funds own 44.29% of the company’s stock.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.